Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 20Gastrointestinal 5Lymphoid 3Genitourinary 3Gynecologic 2Dermatologic 2CNS 2Breast 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Large B-Cell, Diffuse 5Neoplasm Metastasis 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Hodgkin Disease 4Sarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 6Cyclophosphamide 6X-Rays 5Phantoms, Imaging 5Filgrastim 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Gemcitabine 4Biopsy 4tazemetostat 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Etoposide 3Drug Therapy 3Carboplatin 3Busulfan 3Bevacizumab 3ulixertinib 2tipifarnib 2spartalizumab 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ganitumab 2ensartinib 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma × Bevacizumab × Lymphoid × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡